RS102504A - Method for the protection of endothelial and epithelial cells during chemotherapy - Google Patents

Method for the protection of endothelial and epithelial cells during chemotherapy

Info

Publication number
RS102504A
RS102504A YU102504A YUP102504A RS102504A RS 102504 A RS102504 A RS 102504A YU 102504 A YU102504 A YU 102504A YU P102504 A YUP102504 A YU P102504A RS 102504 A RS102504 A RS 102504A
Authority
RS
Serbia
Prior art keywords
endothelial
protection
epithelial cells
cells during
during chemotherapy
Prior art date
Application number
YU102504A
Other languages
English (en)
Inventor
Gunther Eissner
Ernst Holler
Original Assignee
Universitat Regensburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat Regensburg filed Critical Universitat Regensburg
Publication of RS102504A publication Critical patent/RS102504A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Ovaj pronalazak je usmeren na upotrebu zaštitnog oligodezoksiribonukleotida u tretmanu pacijenta koji će biti podvrgnut tretmanu sa imunosupresivnim lekom. Pronalazak je dalje usmeren na farmaceutski preparat koji sadrži terapeutski efektivnu dozu imunosupresivnog leka i zaštitnog oligodezoksiribonukleotida.
YU102504A 2002-05-31 2003-06-02 Method for the protection of endothelial and epithelial cells during chemotherapy RS102504A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38411402P 2002-05-31 2002-05-31
US38743802P 2002-06-11 2002-06-11
PCT/EP2003/005753 WO2003101468A1 (en) 2002-05-31 2003-06-02 Method for the protection of endothelial and epithelial cells during chemotherapy

Publications (1)

Publication Number Publication Date
RS102504A true RS102504A (en) 2006-12-15

Family

ID=29715309

Family Applications (1)

Application Number Title Priority Date Filing Date
YU102504A RS102504A (en) 2002-05-31 2003-06-02 Method for the protection of endothelial and epithelial cells during chemotherapy

Country Status (16)

Country Link
EP (1) EP1509235A1 (sr)
JP (1) JP2005527636A (sr)
CN (1) CN1304011C (sr)
AU (1) AU2003238189A1 (sr)
CA (1) CA2487171A1 (sr)
EA (1) EA008213B1 (sr)
HR (1) HRP20041213A2 (sr)
IL (1) IL165353A0 (sr)
IS (1) IS7548A (sr)
MX (1) MXPA04011941A (sr)
NO (1) NO20045655L (sr)
NZ (1) NZ536864A (sr)
PL (1) PL374402A1 (sr)
RS (1) RS102504A (sr)
UA (1) UA83628C2 (sr)
WO (1) WO2003101468A1 (sr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
DK2637672T3 (en) 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
WO2013190582A1 (en) 2012-06-22 2013-12-27 Gentium S.P.A. Euglobulin-based method for determining the biological activity of defibrotide
EP3026122A1 (en) * 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048843A1 (en) * 1997-04-28 1998-11-05 Arsinur Burcoglu Method of treating hiv infection and related secondary infections thereof

Also Published As

Publication number Publication date
AU2003238189A1 (en) 2003-12-19
MXPA04011941A (es) 2005-07-26
UA83628C2 (ru) 2008-08-11
CA2487171A1 (en) 2003-12-11
EA200401448A1 (ru) 2005-06-30
IS7548A (is) 2004-11-24
HRP20041213A2 (en) 2006-04-30
PL374402A1 (en) 2005-10-17
NO20045655L (no) 2004-12-27
EA008213B1 (ru) 2007-04-27
CN1304011C (zh) 2007-03-14
NZ536864A (en) 2008-08-29
EP1509235A1 (en) 2005-03-02
CN1655801A (zh) 2005-08-17
JP2005527636A (ja) 2005-09-15
IL165353A0 (en) 2006-01-15
WO2003101468A1 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
MXPA05013642A (es) Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer.
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
GEP20033092B (en) Purine Inhibitors of Cyclin Dependent Kinase 2 and Ik-Aa
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
BG106104A (en) Method for the treatment of diseases related to increased number of neutrophils or neutrophil overactivation
UA89035C2 (ru) Эфиры гидроксамовых кислот и их фармацевтическое применение
BG106461A (en) Methods and use of rapid onset of reactive serotonin inhibitors for treating sexual dysfunction
UA41355C2 (uk) Засіб для лікування нейро-сніду
MXPA02011247A (es) Quimioterapia de combinacion.
ATE247709T1 (de) 3'utr des menschliches prohibitin-gens
GB0130677D0 (en) Medicaments and novel compounds
MD2196B2 (ro) Criptoficine, procedeu de obţinere, compoziţii farmaceutice pe baza acestora, metodă de inhibare a proliferării celulelor mamiferelor şi metodă de atenuare a stării patologice cauzate de hiperproliferarea celulelor mamiferelor
GEP20012389B (en) Benzoxazinone Dopamine D4 Receptor Antagonists, Pharmaceutical Composition Containing the Same and Method for Treatment of Psychosis or Schizophrenia
IL132853A (en) Composition for modulating the human sexual response
MXPA04011835A (es) Tratamiento de combinacion para la depresion y ansiedad.
RS102504A (en) Method for the protection of endothelial and epithelial cells during chemotherapy
NO984920D0 (no) Sammensetninger omfattende en nitroneforbindelse for anvendelse ved behandling av okulµr inflammasjon
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
DE60236927D1 (de) Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
ATE374025T1 (de) Verbindungen zur beseitigung und/oder linderung der anhedonie
MX2022011188A (es) Derivado biciclico fusionado, metodo de preparacion y uso farmaceutico del mismo.
GB0202337D0 (en) Cancer treatment
AU2003281257A8 (en) A novel use of rapamycin and structural analogues thereof
IL136225A0 (en) Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation